GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has ...

The data showed that a vaccine candidate produced positive immune responses against both A and B flu strains in younger and ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage ...

GSK has reported positive results from its phase II trial for an mRNA seasonal influenza vaccine candidate, showing strong immune responses again ...

GSK has shared positive headline results for its mRNA seasonal influenza vaccine and outlined that it will now progress the ...

British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine ...

GSK announced positive Phase II results for its mRNA seasonal influenza vaccine, showing strong immune responses against ...

Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech. Interim data suggest the vaccine candidates have an acceptable safety and ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...

The data demonstrated positive immune responses against influenza A and B strains compared to the current standard of care. With these results, the GSK mRNA seasonal influenza vaccine program will ...